Atrium Medical filed four petitions with the Patent Trial and Appeals Board for inter partes review of C.R. Bard’s U.S. Patent No. 7,785,334. The ‘334 patent, entitled “Implantable Prosthesis” issued on August 31, 2010. According to the ‘334 patent, the patent relates to an “implantable prosthesis for repairing an anatomical defect, such as a tissue or muscle wall hernia” and “includes a patch and/or plug having a body portion that is larger than a portion of the opening or weakness so that placement of the body portion against the defect will cover or extend across that portion of the opening or weakness.” Figure 1 from the ‘334 patent is shown below:
Two of the four petitions are currently publicly available, seeking review of Claims 24-49 and Claims 99-126. The exhibit titles can be seen by visiting the Board’s website, searching for the ‘334 patent, and clicking on the Case Number link.
According to Atrium’s website, Atrium’s ProLite™ and ProLite Ultra™ brand polypropylene surgical mesh products are commonly used for soft tissue and hernia repair and employ Atrium’s C-QUR™ Mesh technology, which utilizes a proprietary, pharmaceutical grade Omega 3 Bioabsorbable Oil Fatty Acid (O3FA) coated surgical mesh.